The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Lewis Alan since 2007.
The trader's CIK number is 1207604.
At the time of the last reporting, Lewis Alan was the Director of Biomarin Pharmaceutical Inc. (stock ticker symbol BMRN).
Also see all insider trading activities at Biomarin Pharmaceutical Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | BMRN | 0 | $0 | 11,700 | $1,163,727 | 7,500 | $107,925 |
| 2014 | BMRN | 0 | $0 | 7,500 | $674,227 | 7,500 | $161,325 |
| 2013 | BMRN | 0 | $0 | 45,000 | $2,845,732 | 45,000 | $1,290,825 |
| 2012 | BMRN | 0 | $0 | 55,000 | $2,204,760 | 45,000 | $686,249 |
| 2007 | BMRN | 0 | $0 | 20,000 | $402,680 | 30,000 | $231,600 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-08-28 | BMRN | Option Ex | 7,500 | 14.39 | 107,925 |
| 2018-08-28 | BMRN | Sale | 7,500 | 99.11 | 743,362 |
| 2018-08-21 | BMRN | Sale | 4,200 | 100.09 | 420,365 |
| 2014-12-04 | BMRN | Option Ex | 7,500 | 21.51 | 161,325 |
| 2014-12-04 | BMRN | Sale | 7,500 | 89.90 | 674,227 |
| 2013-12-09 | BMRN | Option Ex | 22,500 | 32.54 | 732,150 |
| 2013-12-09 | BMRN | Sale | 22,500 | 69.91 | 1,572,975 |
| 2013-02-27 | BMRN | Option Ex | 22,500 | 24.83 | 558,675 |
| 2013-02-27 | BMRN | Sale | 22,500 | 56.57 | 1,272,757 |
| 2012-11-07 | BMRN | Option Ex | 15,000 | 17.33 | 259,949 |
| 2012-11-07 | BMRN | Sale | 15,000 | 46.80 | 702,000 |
| 2012-08-06 | BMRN | Option Ex | 30,000 | 14.21 | 426,300 |
| 2012-08-06 | BMRN | Sale | 40,000 | 37.57 | 1,502,760 |
| 2007-08-10 | BMRN | Option Ex | 30,000 | 7.72 | 231,600 |
| 2007-08-10 | BMRN | Sale | 20,000 | 20.13 | 402,680 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lewis Alan (Director of Biomarin Pharmaceutical Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.